| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
118,790,000 |
| Market
Cap: |
42.71(M) |
| Last
Volume: |
19,275,386 |
Avg
Vol: |
8,983,226 |
| 52
Week Range: |
$0.3595 - $0.3595 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M™ adjuvant.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
6,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcmanus Michael A Jr |
Director |
– • – |
2021-06-25 |
4/A |
OE |
$0.00 |
$0 |
D/D |
3,450 |
9,401 |
|
- |
|
| King Rachel K. |
Director |
– • – |
2021-06-25 |
4/A |
OE |
$0.00 |
$0 |
D/D |
3,450 |
6,250 |
|
- |
|
| Mcmanus Michael A Jr |
Director |
– • – |
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,900 |
12,851 |
|
- |
|
| Douglas Richard |
Director |
– • – |
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,450 |
31,950 |
|
- |
|
| King Rachel K. |
Director |
– • – |
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,900 |
9,700 |
|
- |
|
| Herrmann John A Iii |
EVP, Chief Legal Officer |
• – – |
2021-06-25 |
4 |
D |
$189.79 |
$76,485 |
D/D |
(403) |
706 |
|
- |
|
| Herrmann John A Iii |
EVP, Chief Legal Officer |
• – – |
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
834 |
1,109 |
|
- |
|
| Young James F |
Director |
– • – |
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,590 |
65,090 |
|
- |
|
| Trizzino John |
EVP, CCO, CBO & Interim CFO |
• – – |
2021-06-25 |
4 |
D |
$189.79 |
$76,485 |
D/D |
(403) |
718 |
|
- |
|
| Trizzino John |
EVP, CCO, CBO & Interim CFO |
• – – |
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
834 |
1,121 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2021-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,450 |
19,549 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-06-17 |
4 |
AS |
$183.28 |
$441,887 |
D/D |
(2,411) |
2,811 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-06-15 |
4 |
D |
$187.07 |
$421,656 |
D/D |
(2,254) |
5,222 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-06-15 |
4 |
D |
$187.07 |
$28,809 |
D/D |
(154) |
7,476 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-06-15 |
4 |
OE |
$5.95 |
$138,685 |
D/D |
10,535 |
7,630 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-06-15 |
4 |
AS |
$183.53 |
$1,094,130 |
D/D |
(5,716) |
2,811 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2021-06-01 |
4 |
S |
$146.50 |
$91,563 |
I/I |
(625) |
0 |
|
- |
|
| Herrmann John A Iii |
EVP, Chief Legal Officer |
• – – |
2021-05-28 |
4 |
AS |
$147.85 |
$431,748 |
D/D |
(2,895) |
275 |
|
- |
|
| Herrmann John A Iii |
EVP, Chief Legal Officer |
• – – |
2021-05-28 |
4 |
OE |
$5.95 |
$42,933 |
D/D |
2,895 |
3,170 |
|
- |
|
| King Rachel K. |
Director |
– • – |
2021-05-19 |
4 |
B |
$139.64 |
$97,748 |
D/D |
700 |
2,800 |
2.39 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-05-19 |
4 |
AS |
$138.29 |
$339,066 |
D/D |
(2,385) |
2,811 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-05-17 |
4 |
D |
$140.16 |
$312,417 |
D/D |
(2,229) |
5,196 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-05-17 |
4 |
D |
$140.16 |
$28,733 |
D/D |
(205) |
7,425 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-05-17 |
4 |
OE |
$5.95 |
$138,577 |
D/D |
10,531 |
7,630 |
|
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2021-05-17 |
4 |
AS |
$131.50 |
$765,267 |
D/D |
(5,712) |
2,811 |
|
- |
|
602 Records found
|
|
Page 9 of 25 |
|
|
